Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with biopsy-proven metastatic carcinoid tumors
Patients with at least one measurable lesion (excluding bone)
Patients must be considered inadequately controlled while on Sandostatin LAR therapy based on the symptoms of carcinoid syndrome (diarrhea and/or flushing) as defined as experiencing a minimum average of at least four bowel movements per day or a minimum average of at least two episodes of flushing per day
You may not be if
Patients who have been previously treated with certain medications may be required to be without certain medications prior to entering the study
Patients who have undergone major recent surgery / surgical therapy for any cause within 1 month
Patients on any cytotoxic chemotherapy or interferon therapy within the last 2 months
Patients with uncontrolled diabetes mellitus
Patients who had received radiotherapy for any reason within the last 4 weeks must have recovered from any side effects of radiotherapy
Patients who have congestive heart failure unstable angina, cardiac arrhythmia or a history of acute myocardial infarction within the three months preceding enrollment
Patients with chronic liver disease
Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method for birth control.
History of immunocompromise, including a positive HIV test result
Patients who have a history of alcohol or drug abuse in the 6 month period prior to receiving SOM230
Patients who have given a blood donation (of 400 mL or more) within 2 months before receiving SOM230
Patients who have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
Patients with additional active malignant disease within the last five years
Clareo Health | Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
